Departamento de Bioingeniería e Ingeniería Aeroespacial, Universidad Carlos III de Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain; Diseases of the Developing World, Infectious Diseases-Centre for Excellence in Drug Discovery (ID CEDD), GlaxoSmithKline, Madrid, Spain.
Departamento de Bioingeniería e Ingeniería Aeroespacial, Universidad Carlos III de Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
Tuberculosis (Edinb). 2020 Mar;121:101918. doi: 10.1016/j.tube.2020.101918. Epub 2020 Mar 3.
The sensitivity of in vivo low-dose high-resolution micro-computed tomography imaging enables monitoring the lung damage caused by tuberculosis. Here, we propose a radiological score integrated in the experimental workflow that enables longitudinal monitoring for prospective efficacy studies in drug development programs. The score is based on an automatic measurement of total unaffected lung volume in vivo normalized for inter-subject comparison. It was validated on well-characterized progression of chronic tuberculosis in Erdman and H37Rv strains in C3HeB/FeJ-based models. We demonstrated that a decrease in the score value indicates increasing adverse effects and vice versa. The colony-forming units count confirmed the variability in the host response suggested by the score values. The correlation between changes in the mice's weight and the score is consistent with disease progression. The classification of disease extent by k-means clustering of the score values provided the definition of the lung damage severity according to the bacillus strain. The proposed score will reduce sources of bias and improve the statistical robustness of studies by the attrition of non-infected subjects or subjects with a weak immune response. Readily available quantifications allow for a fast assessment of the therapeutic potential in drug-resistant tuberculosis strains.
体内低剂量高分辨率微计算机断层扫描成像的灵敏度能够监测结核病引起的肺部损伤。在这里,我们提出了一种放射学评分,该评分集成在实验工作流程中,能够进行前瞻性疗效研究,以评估药物开发计划中的药物。该评分基于对体内未受影响的总肺体积进行自动测量,并进行了标准化,以进行受试者间比较。该评分在 Erdman 和 H37Rv 菌株的慢性结核病的特征明确的进展以及基于 C3HeB/FeJ 的模型中得到了验证。我们证明,评分值的降低表明不良反应增加,反之亦然。集落形成单位计数证实了评分值所提示的宿主反应的可变性。体重变化与评分之间的相关性与疾病进展一致。根据杆菌株对评分值进行 k-均值聚类的分类为肺损伤严重程度提供了定义。该评分将通过剔除未感染的受试者或免疫反应较弱的受试者,减少偏倚来源,并通过减少非感染受试者或免疫反应较弱的受试者,提高研究的统计稳健性。易于获得的定量分析可快速评估耐药结核菌株的治疗潜力。